Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity

Chemotherapeutic agents are generally used as a frontline therapy for non-small cell lung cancer (NSCLC). However, resistance to chemotherapy arises rapidly in NSCLC, and the reasons for chemotherapy resistance have not been fully determined. Here, we found cisplatin, but not paclitaxel and doxorubi...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cell Death Dis
Asıl Yazarlar: Wang, Lihui, Liu, Xing, Ren, Yong, Zhang, Jingyuan, Chen, Junli, Zhou, Wenlong, Guo, Wei, Wang, Xiaoxuan, Chen, Huiping, Li, Meng, Yuan, Xiangzhong, Zhang, Xun, Yang, Jingyu, Wu, Chunfu
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2017
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5477570/
https://ncbi.nlm.nih.gov/pubmed/28406482
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cddis.2016.409
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller